HDAC family: What are the cancer relevant targets?

Cited by (1,000)

Items 101–200 of 1,000

1. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer
   Mei-Yi Wu, Junjiang Fu, Xiuli Xiao, Jingbo Wu, Ray‐Chang Wu · 2014 · Cancer Letters
2. Design, Synthesis, Docking, and Biological Evaluation of Novel Diazide-Containing Isoxazole- and Pyrazole-Based Histone Deacetylase Probes
   Raghupathi Neelarapu, Denise L. Holzle, Subash Velaparthi, He Bai, Michael Brunsteiner, Sylvie Y. Blond, Pavel A. Petukhov · 2011 · Journal of Medicinal Chemistry
3. Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells
   Madhumita Roy, Sutapa Mukherjee · 2014 · Asian Pacific Journal of Cancer Prevention
4. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder
   Stefania Trazzi, Claudia Fuchs, Rocchina Viggiano, Marianna De Franceschi, Emanuele Valli, Paulina Jedynak, Finn Kristian Hansen, Giovanni Perini, Roberto Rimondini, Thomas Kurz et al. · 2016 · Human Molecular Genetics
5. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma
   Anjali Mishra, Krista La Perle, Sonya Kwiatkowski, Laura A. Sullivan, Gregory H. Sams, Jessica Johns, Douglas P. Curphey, Jing Wen, Kathleen K. McConnell, Jun Qi et al. · 2016 · Cancer Discovery
6. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease
   Nobuhide Ueki, Siyeon Lee, Nicole S. Sampson, Michael J. Hayman · 2013 · Nature Communications
7. European Perspective on Multiple Myeloma Treatment Strategies in 2014
   Heinz Ludwig, Pieter Sonneveld, Faith E. Davies, Joan Bladé, Mario Boccadoro, Michèle Cavo, Gareth John Morgan, Javier de la Rubia, Michel Delforge, Meletios Athanasios Dimopoulos et al. · 2014 · The Oncologist
8. Histone deacetylases function as novel potential therapeutic targets for cancer
   Hui Zhang, Yuping Shang, Hong‐ying Chen, Jun Li · 2016 · Hepatology Research
9. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
   Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian et al. · 2019 · Journal of Medicinal Chemistry
10. Introducing the acetylome
    Karen T. Smith, Jerry L. Workman · 2009 · Nature Biotechnology
11. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
    Marco Lodrini, Ina Oehme, Christina Schroeder, Till Milde, Marie C. Schier, Annette Kopp‐Schneider, Johannes Hubertus Schulte, Matthias Fischer, Katleen De Preter, Filip Pattyn et al. · 2013 · Nucleic Acids Research
12. Transcription and beyond: the role of mammalian class I lysine deacetylases
    M. Moser, Astrid Hagelkrüys, Christian Seiser · 2013 · Chromosoma
13. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
    Eugene Guorong Yang, Nurulhuda Binte Mustafa, Eng Chong Tan, Anders Poulsen, Pondy Murugappan Ramanujulu, Wee Joo Chng, Jeffrey J. Y. Yen, Brian William Dymock · 2016 · Journal of Medicinal Chemistry
14. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
    Magalie N. E. Géraldy, Michael Morgen, Peter A. Sehr, Raphael R. Steimbach, Davide Moi, Johannes Ridinger, Ina Oehme, Olaf Witt, Mona Malz, Mauro S. Nogueira et al. · 2019 · Journal of Medicinal Chemistry
15. HDAC1 and HDAC2 in mouse oocytes and preimplantation embryos: Specificity versus compensation
    Pengpeng Ma, Richard M. Schultz · 2016 · Cell Death and Differentiation
16. Aberrant Regulation of HDAC2 Mediates Proliferation of Hepatocellular Carcinoma Cells by Deregulating Expression of G1/S Cell Cycle Proteins
    Ji Heon Noh, Kwang Hwa Jung, Jeong Kyu Kim, Jung Woo Eun, Hyun Jin Bae, Hong Jian Xie, Young Gyoon Chang, Min Kim, Won Sang Park, Jung Young Lee et al. · 2011 · PLoS ONE
17. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
    Jessica J. Chang, Diana Varghese, M C Gillam, Michael Peyton, Badri G. Modi, R. Louis Schiltz, Luc Girard, Elisabeth D. Martínez · 2011 · British Journal of Cancer
18. Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile
    Haishan Wang, Niefang Yu, Dizhong Chen, Ken Chi Lik Lee, Pek Ling Lye, Joyce Wei Wei Chang, Weiping Deng, Melvin Ng, Ting Lu, Mui Ling Khoo et al. · 2011 · Journal of Medicinal Chemistry
19. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
    Li, Xiaoyang, Peterson, Yuri K., Inks, Elizabeth S., Himes, Richard A., Li, Jiaying, Zhang, Yingjie, Kong, Xiujie, Chou, C. James · 2018 · Journal of Medicinal Chemistry
20. Retinoic Acid and Histone Deacetylases Regulate Epigenetic Changes in Embryonic Stem Cells
    Alison M. Urvalek, Lorraine J. Gudas · 2014 · Journal of Biological Chemistry
21. Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
    Ramamurthi Vidya Priyadarsini, Siddavaram Nagini · 2011 · Current Pharmaceutical Biotechnology
22. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
    Annunziata Gloghini, Daniela Buglio, Noor M. Khaskhely, Georgios V. Georgakis, Robert Zygmunt Orlowski, Sattva Swarup Neelapu, Antonino Carbone, Anas Younes · 2009 · British Journal of Haematology
23. Pluripotent stem cell differentiation into vascular cells: A novel technology with promises for vascular re(generation)
    Nicole M. Kane, Qingzhong Xiao, Andrew Howard Baker, Zhenling Luo, Qingbo Xu, Costanza Emanueli · 2010 · Pharmacology & Therapeutics
24. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
    Ping Zhang, Mingzhi Zhang · 2020 · Clinical Epigenetics
25. Chemo-proteomics exploration of HDAC degradability by small molecule degraders
    Yuan Xiong, Katherine A. Donovan, Nicholas A. Eleuteri, Nadia Kirmani, Hong Yue, Anthony Razov, Noah M. Krupnick, Radosław P. Nowak, Eric S. Fischer · 2021 · Cell chemical biology
26. Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges
    Bocheng Wu, Quaovi H. Sodji, Adegboyega K. Oyelere · 2022 · Cancers
27. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
    Kai Cao, Guanghui Wang, W Li, Li Zhang, R Wang, Yigang Huang, Liming Du, Jingting Jiang, Chao‐Liang Wu, Xiaping He et al. · 2015 · Oncogene
28. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease
    Obdulia Rabal, Juan Antonio Sánchez-Arias, Mar Cuadrado‐Tejedor, Irene de Miguel, Marta Pérez-González, Carolina García, Ana Ugarte, Ander Estella‐Hermoso de Mendoza, Elena Sáez, María Espelosin et al. · 2016 · Journal of Medicinal Chemistry
29. HDAC3 is essential for DNA replication in hematopoietic progenitor cells
    Summers, Alyssa R., Fischer, Melissa A., Stengel, Kristy R., Zhao, Yue, Kaiser, Jonathan F., Wells, Christina E., Hunt, Aubrey, Bhaskara, Srividya, Luzwick, Jessica W., Sampathi, Shilpa et al. · 2013 · Journal of Clinical Investigation
30. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer
    Wenjing Wang, Mengyue Zhao, Lijuan Cui, Yong Ren, Jingyuan Zhang, Junli Chen, Lina Jia, Jiayu Zhang, Jingyu Yang, Guoliang Chen et al. · 2020 · Molecular Cancer
31. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance
    Michaël Van Damme, Emerence Crompot, Nathalie Meuleman, Philippe Mineur, D Bron, Laurence Lagneaux, Basile Stamatopoulos · 2012 · Epigenetics
32. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
    Cynthia A. Zahnow, Michael J. Topper, Meredith L. Stone, Tracy Murray Stewart, H. Li, Stephen B. Baylin, Robert A. Casero · 2016 · Advances in cancer research
33. Mechanical regulation of epigenetics in vascular biology and pathobiology
    Li‐Jing Chen, Shu‐Yi Wei, Jeng‐Jiann Chiu · 2013 · Journal of Cellular and Molecular Medicine
34. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
    Yongtao Li, Xiaohe Luo, Qingxiang Guo, Yongwei Nie, Tianqi Wang, Chao Zhang, Zhi Huang, Xin Wang, Yanhua Liu, Yanan Chen et al. · 2018 · Journal of Medicinal Chemistry
35. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
    Xiaopeng Peng, Zhihao Hu, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Wei‐Ming Chen, Wen Hou, Kui Cheng et al. · 2023 · Acta Pharmaceutica Sinica B
36. Role of HDAC1 in senescence, aging, and cancer
    Danielle Willis-Martinez, Hunter W. Richards, Nikolai A. Timchenko, Estela E. Medrano · 2009 · Experimental Gerontology
37. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
    Chiara Giommarelli, Valentina Zuco, Enrica Favini, Claudio Pisano, Fabrizio Dal Piaz, Nunziatina De Tommasi, Franco Zunino · 2009 · Cellular and Molecular Life Sciences
38. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
    Tobias Wagner, Peter Brand, Thorsten Heinzel, Oliver Holger Krämer · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
39. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
    Jia-Rong Liu, Chao‐Wu Yu, Pei-Yun Hung, Ling‐Wei Hsin, Ji‐Wang Chern · 2019 · Biochemical Pharmacology
40. HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
    Kuen‐Tyng Lin, Yiwei Wang, Chiung‐Tong Chen, Chun‐Ming Ho, Wen-Hui Su, Yuh‐Shan Jou · 2012 · Clinical Cancer Research
41. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
    Susanne Schüler, Petra Fritsche, Sandra Diersch, Alexander Arlt, Roland Michael Schmid, Dieter Saur, Günter Schneider · 2010 · Molecular Cancer
42. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review
    Hassan Mesgari, Samar Esmaelian, Kamyar Nasiri, Shabnam Ghasemzadeh, Parisa Doroudgar, Zahra Payandeh · 2023 · Cancers
43. Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
    Andreas Sellmer, Hubert Stangl, Mandy Beyer, Elisabeth Grünstein, Michel Leonhardt, Herwig Pongratz, Emerich Eichhorn, Sigurd Elz, Birgit Striegl, Zsuzsa Jenei‐Lanzl et al. · 2018 · Journal of Medicinal Chemistry
44. Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer
    Aamod S. Dekhne, Zhanjun Hou, Aleem Gangjee, Larry H. Matherly · 2020 · Molecular Cancer Therapeutics
45. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages
    Finn K. Hansen, Subathdrage D.M. Sumanadasa, Katharina Stenzel, Sandra Duffy, Stephan Meister, Linda Marek, Rebekka Schmetter, Krystina Kuna, Alexandra Hamacher, Benjamin G. Mordmüller et al. · 2014 · European Journal of Medicinal Chemistry
46. Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
    Madeline Wong, Chun Hua Guo, Jinsong Zhang · 2014 · PubMed Central
47. What Causes a Broken Heart—Molecular Insights into Heart Failure
    Seán P. Barry, Paul A. Townsend · 2010 · International review of cytology
48. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
    Cédric Poyet, Bastian Jentsch, Thomas Hermanns, Daniel Schweckendiek, Hans‐Helge Seifert, Martin Schmidtpeter, Tullio Sulser, Holger Moch, Peter Johannes Wild, Glen Kristiansen · 2014 · BMC Clinical Pathology
49. Changing the Selectivity of p300 by Acetyl-CoA Modulation of Histone Acetylation
    Ryan A. Henry, Yin‐Ming Kuo, Vikram Bhattacharjee, Tim J. Yen, Andrew J. Andrews · 2014 · ACS Chemical Biology
50. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)
    Li, Yunheng, Sang, Shenghu, Ren, Weijie, Pei, Yuqiong, Bian, Yaoyao, Chen, Yao, Sun, Haopeng · 2021 · European Journal of Medicinal Chemistry
51. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
    Xuan Zhang, Jie Zhang, Linjiang Tong, Yu Luo, Mingbo Su, Yi Zang, Jia Xuan Li, Wei Ping Lu, Yi Chen · 2013 · Bioorganic & Medicinal Chemistry
52. A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
    Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Sophie Kristeleit, Phillip M. Debnam, Matthew Tall, Adam Stewart, Florence I. Raynaud, Michelle Dawn Garrett, Martin Toal et al. · 2012 · Clinical Cancer Research
53. Effects of novel HDAC inhibitors on urothelial carcinoma cells
    Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, Ananda Ayyappan Jaguva Vasudevan, Chenyin Wang, Finn K. Hansen, Constanze Wiek, Helmut Hanenberg, Christoph G. W. Gertzen, Holger Gohlke et al. · 2018 · Clinical Epigenetics
54. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer
    Kamalpreet Kaur, Vikas Jaitak · 2019 · Anti-Cancer Agents in Medicinal Chemistry
55. The Use of Conformational Restriction in Medicinal Chemistry
    Pedro de Sena Murteira Pinheiro, Daniel Alencar Rodrigues, Rodolfo do Couto Maia, Sreekanth Thota, Carlos Alberto Manssour Fraga · 2019 · Current Topics in Medicinal Chemistry
56. Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment
    Jhih-Bin Chen, Ting‐Rong Chern, Tzu-Tang Wei, Ching‐Chow Chen, Jung‐Hsin Lin, Jim‐Min Fang · 2013 · Journal of Medicinal Chemistry
57. Histone deacetylases and their roles in mineralized tissue regeneration
    Nam Cong‐Nhat Huynh, Vincent E. Everts, Ruchanee Salingcarnboriboon Ampornaramveth · 2017 · Bone Reports
58. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
    Yemin Wang, Shary Yuting Chen, Shane Colborne, Galen Lambert, Chae Young Shin, Nancy Dos Santos, Krystal A. Orlando, Jessica D. Lang, William P.D. Hendricks, Marcel B. Bally et al. · 2018 · Molecular Cancer Therapeutics
59. Deacetylase Inhibitors Dissociate the Histone-Targeting ING2 Subunit from the Sin3 Complex
    Karen T. Smith, Skylar Martin‐Brown, Laurence A. Florens, Michael P. Washburn, Jerry L. Workman · 2010 · Chemistry & Biology
60. Targeting of HDAC8 and investigational inhibitors in neuroblastoma
    Ina Oehme, Hedwig E. Deubzer, Marco Lodrini, Till Milde, Olaf Witt · 2009 · Expert Opinion on Investigational Drugs
61. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers
    Günter Niegisch, Judith Knievel, Annemarie Koch, Christiane Hader, Ute Fischer, Peter Albers, Wolfgang A. Schulz · 2012 · Urologic Oncology Seminars and Original Investigations
62. Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity
    Işın Çakır, Colleen K. Hadley, Pauline Lining Pan, Rushita Adhikari Bagchi, Masoud Ghamari‐Langroudi, Danielle T. Porter, Qiuyu Wang, Michael J. Litt, Somnath Jana, Susan E. Hagen et al. · 2022 · Nature Metabolism
63. Structural basis for the design and synthesis of selective HDAC inhibitors
    Simone Di Micco, Maria Giovanna Chini, Stefania Terracciano, Ines Bruno, Raffaele Riccio, Giuseppe Bifulco · 2013 · Bioorganic & Medicinal Chemistry
64. HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
    Emily Koeneke, Olaf Witt, Ina Oehme · 2015 · Cells
65. Chemopreventive and Anti-Cancer Efficacy of Silibinin Against Growth and Progression of Lung Cancer
    Samiha Mateen, Komal Raina, Rajesh Agarwal · 2013 · Nutrition and Cancer
66. Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering
    Liam Lawlor, Xuebin Yang · 2019 · International Journal of Oral Science
67. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
    Laura Sinatra, Jan Josef Bandolik, Martin Roatsch, Melf Sönnichsen, Clara T. Schoeder, Alexandra Hamacher, Andrea Schöler, Arndt Borkhardt, Jens Meiler, Sanil Bhatia et al. · 2020 · Angewandte Chemie International Edition
68. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy
    Manasa Gangadhar Shetty, Padmini Pai, Renita Esther Deaver, Kapaettu Satyamoorthy, Kampa Sundara Babitha · 2021 · Pharmacological Research
69. Genetic and epigenetic changes in lung carcinoma and their clinical implications
    Jing Wen, Jianhua Fu, Wei Zhang, Ming Guo · 2011 · Modern Pathology
70. Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer
    Matthew Riolo, Zachary Aaron Cooper, Michael P. Holloway, Yan Cheng, Cesario F. Bianchi, Evgeny Yakirevich, Li Ma, Yue Eugene Chin, Rachel A. Altura · 2012 · Journal of Biological Chemistry
71. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
    Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Fernanda Savacini Sagrillo, María Laura Bolognesi, Carlos Alberto Manssour Fraga · 2020 · Medicinal Research Reviews
72. Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis
    Mircea Winter, M. Moser, Dominique Meunier, Carina Fischer, Georg Machat, Katharina Mattes, Beate M. Lichtenberger, Reinhard Brunmeir, Simon Weissmann, Christina Murko et al. · 2013 · The EMBO Journal
73. LSD1 Regulates Pluripotency of Embryonic Stem/Carcinoma Cells through Histone Deacetylase 1-Mediated Deacetylation of Histone H4 at Lysine 16
    Feng Yin, Rongfeng Lan, Xiaoming Zhang, Linyu Zhu, Fangfang Chen, Zhengshuang Xu, Yuqing Liu, Tao Ye, Hong Sun, Fei Lu et al. · 2013 · Molecular and Cellular Biology
74. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
    Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, Jianjun Chen · 2021 · Journal of Medicinal Chemistry
75. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
    Antonio Curcio, Roberta Rocca, Stefano Alcaro, Anna Artese · 2024 · Pharmaceuticals
76. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
    Cinzia Fionda, Alessandra Soriani, Alessandra Zingoni, Angela Santoni, Marco Cippitelli · 2015 · BioMed Research International
77. Targeted Inactivation of HDAC2 Restores p16INK4a Activity and Exerts Antitumor Effects on Human Gastric Cancer
    Jeong Kyu Kim, Ji Heon Noh, Jung Woo Eun, Kwang Hwa Jung, Hyun Jin Bae, Qingyu Shen, Min Gyu Kim, Young Gyoon Chang, Seung-Jin Kim, Won Sang Park et al. · 2012 · Molecular Cancer Research
78. Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis
    Bhawna Rastogi, Satish K. Raut, Naresh Kumar Panda, Vidya Rattan, Bishan Radotra, Madhu Khullar · 2016 · Molecular and Cellular Biochemistry
79. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation
    Rui Yin Song, Yurong Yang, Lei Han, Guangxue Wang, Yong Chun Huang, Wenlong Xue, Yinfang Wang, Lingling Yao, Yichun Zhu · 2018 · Journal of Molecular and Cellular Cardiology
80. Pharmacoinformatic Investigation of Medicinal Plants from East Africa
    Conrad Veranso Simoben, Ammar Qaseem, Aurélien F. A. Moumbock, Kiran K. Telukunta, Stefan Günther, Wolfgang Sippl, Fidele Ntie‐Kang · 2020 · Molecular Informatics
81. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma
    Xiaopeng Peng, Ling Li, Jingxuan Chen, Yichang Ren, Jin Liu, Ziwen Yu, Hao Cao, Jianjun Chen · 2022 · Journal of Medicinal Chemistry
82. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition
    Z Meng, L-F Jia, Y‐H. Gan · 2015 · Oncogene
83. Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors
    Marcel K. W. Mackwitz, Alexandra Hamacher, J.D. Osko, Jana Held, Andrea Schöler, David W. Christianson, Matthias Ulrich Kassack, Finn Kristian Hansen · 2018 · Organic Letters
84. Characterization of Histone Deacetylase Mechanisms in Cancer Development
    Rihan Hai, Liuer He, Guang Shu, Gang Yin · 2021 · Frontiers in Oncology
85. Immune evasion by oncogenic proteins of acute myeloid leukemia
    Shlomo Elias, Rachel Yamin, Lior Golomb, Pinchas Tsukerman, Noah Stanietsky, Dina Ben‐Yehuda, Ofer Mandelboim · 2014 · Blood
86. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
    Kaliszczak, M, Trousil, S, Åberg, O, Perumal, M, Nguyen, Q-D, Aboagye, E O · 2013 · British Journal of Cancer
87. Targeting class I histone deacetylases in cancer therapy
    Geneviève P. Delcuve, Dilshad H. Khan, James Davie · 2012 · Expert Opinion on Therapeutic Targets
88. Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
    Luciana Auzzas, Andreas Larsson, Riccardo Matera, Annamaria Baraldi, Benoît Deschênes-Simard, Giuseppe Giannini, Walter Cabri, Gianfranco Battistuzzi, Grazia Gallo, Andrea Ciacci et al. · 2010 · Journal of Medicinal Chemistry
89. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis
    Xinhuan Wang, Ke Liu, Huimin Gong, Dezhi Li, Wenfeng Chu, Dan Zhao, Xiaofeng Wang, Dongyang Xu · 2020 · Toxicology and Applied Pharmacology
90. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
    Leigh Ellis, Роберто Пили · 2010 · Pharmaceuticals
91. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects
    Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin, Tarun Jha, Balaram Ghosh · 2018 · European Journal of Pharmaceutical Sciences
92. RETRACTED: Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
    Valentina Zuco, Michelandrea De Cesare, Raffaella Cincinelli, Raffaella Nannei, Claudio Pisano, Nadia Zaffaroni, Franco Zunino · 2011 · PLoS ONE · Retracted
93. New perspectives of valproic acid in clinical practice
    Lenka Činčárová, Zbyněk Zdráhal, Jiřı́ Fajkus · 2013 · Expert Opinion on Investigational Drugs
94. New patented histone deacetylase inhibitors
    Haishan Wang, Brian William Dymock · 2009 · Expert Opinion on Therapeutic Patents
95. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms
    Maria Pinkerneil, Michèle J. Hoffmann, René Deenen, Karl Köhrer, Tanja Arent, Wolfgang A. Schulz, Günter Niegisch · 2016 · Molecular Cancer Therapeutics
96. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors
    Zigao Yuan, Qinsheng Sun, Dan Li, Shuangshuang Miao, Shaopeng Chen, Lu Song, Chunmei Gao, Yu Chen, Chunyan Tan, Yuyang Jiang · 2017 · European Journal of Medicinal Chemistry
97. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
    Desi Pan, Qian‐Jiao Yang, Xin Fu, Song Shan, Jing-Zhong Zhu, Kun Zhang, Zhibin Li, Zhiqiang Ning, Xianping Lu · 2014 · MedChemComm
98. Inhibition and Mechanism of HDAC8 Revisited
    Kai Chen, Xiaoxiao Zhang, Yun‐Dong Wu, Olaf Wiest · 2014 · Journal of the American Chemical Society
99. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
    Geoffrey M. Matthews, Parinaz Mehdipour, Leonie A. Cluse, Katrina J. Falkenberg, Eric Wang, Mareike Roth, Fabio Santoro, Eva Vidacs, Kym L. Stanley, Colin M. House et al. · 2015 · Blood
100. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells
     Huang Zhijun, Wang Shusheng, Han Min, Li Jianping, Qin Li-Sen, Dechun Li · 2016 · Tumor Biology